EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Thyroid function test variability and cardiovascular morbidity in hyperthyroidism

Nelli Suonsyrjä, Iina Laihia, Heini Huhtala, Pia Jaatinen, Saara Metso

Clinical Endocrinology · 2023

DOI: 10.1111/cen.14948 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Endocrinology, 2023. Verfasst von Nelli Suonsyrjä und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. Hauptthemen laut MEDLINE: Graves Disease, Hyperthyroidism, Cardiovascular Diseases. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The variability of thyroid function tests (TFTs) during antithyroid drug (ATD) therapy and its association with adverse health outcomes have not been previously studied. The aim of this study was to evaluate the association of TFT variability and cardiovascular morbidity during ATD therapy.

Design

Retrospective cohort study. Patients and Measurements Hyperthyroid patients ( n = 394) treated with ATD therapy at Tampere University Hospital between March 2016 and December 2018 were followed up for a median time of 1.5 years (interquartile range 0.8–2.0). The coefficients of variation (CVs) of the follow‐up thyroid‐stimulating hormone (TSH), free thyroxine (fT4) and free triiodothyronine (fT3) measurements were determined. The associations of TFT variability and baseline clinical factors with cardiovascular disease (CVD) ‐associated hospital visits were assessed with logistic regression analyses.

Results

In the multivariable analyses, age (odds ratio [OR]: 1.06, 95% confidence interval [CI]: 1.03–1.09), male gender (OR: 2.33, 95% CI: 1.03–5.28) and fT4‐CV (OR: 1.02, 95% CI: 1.01–1.04) were independent risk factors for cardiovascular morbidity, whereas baseline positive thyrotropin receptor antibodies (TRAbs) were associated with lower cardiovascular morbidity (OR: 0.29, 95% CI: 0.14–0.61). When the patients with baseline TRAb positivity were studied separately, fT4‐CV was associated with cardiovascular morbidity (OR: 1.03, 95% CI: 1.00–1.05).

Conclusions

During ATD therapy, fT4 variability is associated with an increased cardiovascular morbidity. Although positive TRAbs are associated with a lower cardiovascular morbidity compared with hyperthyroidism with negative autoantibodies, the variability of fT4 is associated with cardiovascular morbidity also in patients with positive TRAbs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graves DiseaseHyperthyroidismCardiovascular DiseasesHumansMaleThyroid Function TestsRetrospective StudiesAntithyroid AgentsTriiodothyronineThyrotropinThyroxine

Stichwörter der Autor:innen

Graves diseaseantithyroid agentscardiovascular diseaseshyperthyroidismthyroid function teststhyroid hormonesthyrotropin receptors

Substanzen

Antithyroid AgentsTriiodothyronineThyrotropinThyroxine

Autor:innen und Institutionen

  • Department of Internal Medicine, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • Department of Internal Medicine, Faculty of Social Sciences, Tampere University, Tampere, Finland.
  • Department of Internal Medicine, Tampere University Hospital, Tampere, Finland.
  • Division of Internal Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland.

Zitieren

APA

Suonsyrjä, N., Laihia, I., Huhtala, H., Jaatinen, P., & Metso, S. (2023). Thyroid function test variability and cardiovascular morbidity in hyperthyroidism. Clinical Endocrinology. https://doi.org/10.1111/cen.14948

Vancouver

Suonsyrjä N, Laihia I, Huhtala H, Jaatinen P, Metso S. Thyroid function test variability and cardiovascular morbidity in hyperthyroidism. Clinical Endocrinology. 2023. doi:10.1111/cen.14948

BibTeX
@article{Suonsyrj2023,
  author = {Suonsyrjä, Nelli and Laihia, Iina and Huhtala, Heini and Jaatinen, Pia and Metso, Saara},
  title = {Thyroid function test variability and cardiovascular morbidity in hyperthyroidism},
  journal = {Clinical Endocrinology},
  year = {2023},
  doi = {10.1111/cen.14948}
}
Kostenlos starten →